Critical Considerations for Mesenchymal Stem Cell-based Therapies in Osteoarthritis and Spinal Cord Injury: A Narrative Review - PubMed

7 hours ago

Mesenchymal stem cells (MSCs) are explored for treating degenerative diseases like osteoarthritis (OA) and spinal cord injury (SCI), but clinical outcomes vary.
Analysis of ClinicalTrials.gov and PubMed identified ~1,600 MSC trials, with OA and SCI being the most studied, yet results reporting was low (<7%).
Key factors affecting MSC therapy efficacy include MSC source, donor type, administration details (dose/route/frequency), and patient variation.
Three critical factors for improving efficacy: donor age (affects MSC quality), disease phase (early treatment benefits OA and SCI), and MSC source (autologous preferred over allogeneic).
Autologous MSCs are highlighted for their ability to differentiate and repair without immune interference, suggesting personal MSC banks could enhance therapy success.

Hasty Briefsbeta